Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 5 % of short-term debt in 2025; threshold 65 %.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
-
Busy address KBO
38 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
S-FORM PHARMA from Etterbeek, company number BE0715471307, closed financial year 2025 with a result of € -4,810 after tax. For that financial year S-FORM PHARMA recorded a gross margin of € -3,630 and equity of € -115,150. Compared with financial year 2024, the result moved from € -19,583 to € -4,810. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.
€ -115,150
▼ € 4,810 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -4,810
▲ 75 % less loss than in 2024
Profit after tax over the fiscal year.
€ 359
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -150,150.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 10,511
▲ 158% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -7,049 | € -36,453 | € -18,345 | € -3,630 | ▲ € 14,715 |
| Profit after taxes | € -9,723 | € -38,826 | € -19,583 | € -4,810 | ▲ € 14,773 |
| Equity | € -51,931 | € -90,758 | € -110,340 | € -115,150 | ▼ € 4,810 |
| Total debts | € 87,050 | € 95,979 | € 111,538 | € 135,580 | ▲ 22% |
| Cash | € 32,377 | € 3,964 | € 359 | € 359 | |
| Retained profit | € -86,931 | € -125,758 | € -145,340 | € -150,150 | ▼ € 4,810 |
| Balance sheet total | € 35,119 | € 5,222 | € 1,198 | € 20,430 | ▲ € 19,232 |
Key figures of S-FORM PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to S-FORM PHARMA?
What happened at S-FORM PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 4,810. filed late Source: NBB ↗
- Tatyana ANDREEVA became a director. NBB
- Marcio SCORSIN became a director. NBB
- Eric HALIOUA stepped down as director. NBB
- New establishment in Etterbeek. KBO
- Eric HALIOUA became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 9,723 loss in 2022 to € 4,810 loss in 2025.
A new publication or filing at S-FORM PHARMA? We notify you, reason included.
Follow S-FORM PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Toucan Health Innovations comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
S-FORM PHARMABehind S-FORM PHARMA are Tatyana ANDREEVA and Marcio SCORSIN. The shares are held by Toucan Health Innovations (100%).
Directors
According to the 2025 annual accounts
Tatyana ANDREEVA
Director
since 2024
Marcio SCORSIN
Director
since 2024
since 2018 · until 2024
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Louis Schmidtlaan 87
1040 Etterbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 38 companies are registered at this address.
All companies at this address →Organisatiebureel A.D.
FEDERATION EUROPEENNE DES ASSOCIATIONS DES ETABLISSEMENTS DE CREDIT EUROFINAS ASS INT
€ 462,531 gross margin · 2025
SEGRO BELGIUM
€ -35,308 gross margin · 2025
FEDERATION EUROPEENNE DES ASSOCIATIONS DES ETABLISSEMENTS DE LEASING - EUROPESE FEDERATIE VAN VERENIGINGEN VAN LEASINGONDERNEMINGEN - EUROPEAN FEDERATIONOF LEAS
€ 866,930 gross margin · 2025
IMMOBILIERE PARMA-IMMOBILIEN PARMA
€ -8,614 gross margin · 2025
+33 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0715.471.307
- VAT number
- BE 0715.471.307
- Registered office
- Louis Schmidtlaan 87, 1040 Etterbeek
- Names & denominations
- S-FORM PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 December 2018
- Peppol
- Not registered
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Vervaardiging van overige farmaceutische producten
Handelsbemiddeling in de niet-gespecialiseerde groothandel